Antibody Discovery and Option Agreement Sample Contracts

= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. ANTIBODY DISCOVERY AND OPTION AGREEMENT

Antibody Discovery and Option Agreement • November 13th, 2023 • Apogee Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts

• Contract Type
  Antibody Discovery and Option Agreement
• Filed
  November 13th, 2023
• Company
  Apogee Therapeutics, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  Massachusetts

THIS ANTIBODY DISCOVERY AND OPTION AGREEMENT (“Agreement”) is entered into and effective as of November 9, 2023 (the “Effective Date”), by and between Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), and Apogee Therapeutics, Inc. (“Apogee”), a Delaware corporation. Paragon and Apogee are also referred to herein individually as a “Party”, or collectively as the “Parties.”

ANTIBODY DISCOVERY AND OPTION AGREEMENT

Antibody Discovery and Option Agreement • August 11th, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Massachusetts

• Contract Type
  Antibody Discovery and Option Agreement
• Filed
  August 11th, 2023
• Company
  Aeglea BioTherapeutics, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Massachusetts

This Antibody Discovery and Option Agreement (“Agreement”) is entered into and effective as of May 25, 2023 (the “Effective Date”), by and among Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), Parapyre Holding LLC, a Delaware limited liability company (“Parapyre”) and Spyre Therapeutics, Inc. (“Spyre”), a Delaware corporation. Paragon, Parapyre and Spyre are also referred to herein individually as a “Party”, or collectively as the “Parties.”